Nanotherapeutics

Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics CEO is Guest Panelist at FBR’s Health Series Conference

ALACHUA, FL April 22, 2016. On April 20, FBR hosted a thematic conference featuring 16 guest speakers in four panels to discuss key topics related to infections and diseases, and provided investors a rare opportunity to interact with Robin Robinson, Ph.D., who was most recently the director of the Biomedical Advanced Research and Development Authority (BARDA).   

On the “BARDA Funding Opportunities for Biotech Companies” panel were Dr. Garrett Nichols, CMO of Chimerix; Dr. Jim Talton, CEO of Nanotherapeutics; Stan Erck, CEO of Novavax; and Kelly Childress Lange, partner at East End Group. The main takeaways from the panel were the origins of BARDA and what its role could be in the future for biotech companies. BARDA is meant to fill the gap between early-stage research funded by the NIH and NIAID and later-stage research done by biotech companies. While BARDA was originally funded for 10 years with $5.6 billion, funding now is done by yearly appropriations, meaning it can fluctuate from year to year. However, we note that when an emerging threat presents itself, Congress has typically stepped up to the plate to provide funding. An important aspect going forward could be the award of priority review vouchers for diseases on the Department of Homeland Security’s material threat list, which could then be sold.

Copyright 2016 NANOTHERAPEUTICS, INC.  All rights reserved.